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Abstract Patients with essential thrombocythemia
(ET), who frequently have bleeding complications, may
manifest an excessive prolongation of the bleeding time
(BT) after ingestion of aspirin (ASA). The reason for
this excessive prolongation of the BT is unknown, but it
is attributed to qualitative platelet defects. Since pa-
tients with ET may also have acquired abnormalities of
plasma and platelet von Willebrand factor (vWF), we
questioned whether the excessive prolongation of the
BT by ASA was related to changes in either plasma or
platelet vWF. To that end, we studied BT and plasma
and platelet vWF in ten ET patients, ten patients with
reactive thrombocytosis (RT), and ten normal individu-
als, both before and after administration of 500 mg
ASA for 7 days. In a second study, the effect of
DDAVP infusion on plasma vWF in relation to the BT
was studied in ten normal individuals and ten ET pa-
tients after treatment with 100 mg ASA for 3 days. In
the first study, treatment with ASA resulted in a signif-
icant prolongation of the BT in normal subjects, RT pa-
tients, and ET patients. However, in five ET patients an
excessive (`2 SD) prolongation of the BT by ASA was
observed. Although ASA induced no direct changes in
either plasma or platelet vWF levels in either normal
subjects, RT patients, or ET patients, all five ET pa-
tients who showed an excessive prolongation of the BT
by ASA had significantly decreased levels of large vWF
multimers in plasma. In the second study, infusion with
DDAVP resulted in a significant increase in plasma
large vWF multimers, paralleled by a normalization of
(excessively) prolonged BT. Our data suggest that in
ET inhibition of platelet function by ASA in the pres-
ence of concurrently decreased levels of large vWF
multimers in plasma may have provoked the excessive
BT prolongation.
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Introduction
Excessive bleeding time (BT) prolongation and even
severe bleeding have been observed after administering
aspirin (ASA) to patients with essential thrombocy-
themia (ET) and polycythemia vera (PV) [1, 3, 10, 12,
13]. The reason for the excessive BT prolongation by
ASA is not known, but it is currently attributed to qual-
itative platelet defects [1]. However, abnormal BT pro-
longation after ingestion of ASA is also observed in pa-
tients without dysfunctional platelets. For instance, the
BT after ingestion of ASA has been used to unmask
patients with asymptomatic von Willebrand disease
[11]. Furthermore, in patients with congenital von Wil-
lebrand disease type 3 who lack the ability to synthesize
von Willebrand factor (vWF), a normalization of the
prolonged BT may be obtained with transfusion of nor-
mal platelets after prior cryoprecipitate infusion, sug-
gesting an important role of platelet vWF in platelet-
vessel wall interactions [6]. Since ET patients may exhi-
bit abnormalities of plasma vWF (in particular, reduc-
tion of large vWF multimers) [3, 4, 14, 16], as well as
abnormalities of platelet vWF [5], a study was designed
to find out whether the excessive BT prolongation after
treatment with ASA in ET patients was related to ab-
normalities of plasma or platelet vWF.
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Patients and methods
Design
The study protocol was approved by the local ethics commitee.
The first study was designed to identify ET patients with an ex-
cessive BT prolongation after ingestion of 500 mg ASA (i.e., pro-
longation of BT exceeding the mean c 2 SD BT of normal indi-
viduals after ingestion of ASA) and to investigate the relationship
with changes in plasma or platelet vWF. To that end, a cross-sec-
tional comparison of BT, plasma vWF and platelet vWF-related
parameters was made between ten ET patients, ten reactive
thrombocytosis (RT) patients, and ten control subjects, both be-
fore and after treatment with 500 mg ASA for 7 days. The group
of RT patients was used as a control group to evaluate changes
which might be attributed to an increased platelet count. In a sec-
ond study, DDAVP (Minrin, Ferring BV, Hoofddorp, The Ne-
therlands) was administered intravenously in a dose of 0.4 mg/kg
body wt. to manipulate plasma vWF and its multimeric distribu-
tion and to evaluate the response of ASA-induced (excessively)
prolonged BT to changes in plasma vWF. For this purpose, ten
ET patients and ten control subjects received 100 mg ASA for 3
days before DDAVP infusion to effectively inhibit platelet cyclo-
oxygenase. BT and plasma vWF-related parameters were mea-
sured before, and 1 and 6 h after DDAVP infusion.
Patients
After giving informed consent, ten asymptomatic patients with
ET (six men and four women, ranging in age from 54 to 83 years,
median 62 years) and ten patients with RT (five mean and five
women, ranging in age from 35 to 88 years, median 63 years) par-
ticipated in the first study. The diagnosis of ET was based on
commonly accepted clinical and laboratory criteria [13]. The un-
derlying disorder associated with RT was pyelonephritis in one,
leprosy and iron deficiency in one, psoriasis arthropathica in one,
arteriitis temporalis in one and splenectomy (due to gastric carci-
noma in two, abdominal trauma in three and idiopathic thrombo-
cytopenia in one) in six cases. Ten asymptomatic ET patients
(five men and fivewomen, ranging in age from 21 to 73 years, me-
dian 57 years) with a platelet count of 651B240!109/l partici-
pated in the second study; two of them had also participated in
the first study.
Methods
Platelet counts were determined routinely in whole blood anti-
coagulated with EDTA. For all studies involving vWF, blood was
collected in one-tenth final volume of 3.8% trisodium citrate solu-
tion containing aprotinin, EDTA, and N–ethyl maleimide to give
final concentrations of 500 KIU/ml, 5 mmol/l and 6 mmol/l, re-
spectively. Ivy BT, plasma von Willebrand factor antigen
(vWF:Ag), ristocetin cofactor activity (vWF:RCoF) and collagen
binding activity (vWF:CBA) parameters were measured as de-
scribed previously [14, 15]. Multimeric analysis of plasma and
platelet vWF and the quantification of plasma large vWF multim-
ers was performed as reported in detail elsewhere [4]. Platelet
vWF was assayed in supernatants of platelet lysates. In brief,
platelets were isolated from platelet-rich plasma. This was fol-
lowed by two washings with PBS-EDTA and lysis with 1/10 (v/v)
of 10% Triton X-100 in the presence of 500 KIU/ml aprotinin,
5 mmol/l EDTA and 6 mmol/l N–ethyl maleimide (final concen-
tration), followed by precipitation of cellular fragments by centri-
fugation (10 min at 4 7C; 25000 g). VWF:Ag and vWF:CBA in
platelet lysates were measured as described for plasma vWF,
apart from a standard curve constructed with 1% Triton X-100
(final concentration). Malondialdehyde (MDA) production was
measured in platelet-rich plasma after stimulation of platelets by
arachidonic acid (AA).
Statistics
Analysis of variance (ANOVA), followed by Student-Newman-
Keuls test (SNK test), was used to identify pair-wise significant
differences in group means or differences between the post- and
pre-ASA treatment values (DASA) of normal controls and RT
and ET patients. Correlations between Ivy BT (or DBT) and plas-
ma or platelet vWF parameters (or DASA) were analyzed by lin-
ear regression and Spearman rank order tests. Paired t–tests were
used in the first study to analyze the effect of ASA within each
patient or control group and in the second study to evaluate the
effect of DDAVP within ET patients or normal subjects. In the
second study, plasma vWF parameters and BT of ET patients
were compared with those of normal individuals by Student’s
t–test. Statistical significance was accepted at p~0.05. All data are
expressed as meanBSD.
Results
Pre-ASA treatment values
As shown in Table 1, mean platelet counts were com-
parable in ET and RT patients, and both were signifi-
cantly increased as compared with normal subjects (RT
vs N: p~0.001; ET vs N, p~0.001). Plasma vWF:Ag
and vWF:CBA levels were significantly higher in RT
patients as compared with both ET patients (p~0.05)
and normal individuals (p~0.05). In contrast, per-cen-
tages of plasma large vWF multimers were higher in
normal individuals as compared with both RT patients
(p~0.01) and ET patients (p~0.01), consistent with
previous observations [4, 16]. There were no significant
differences in pre-ASA values of Ivy BT, plasma
vWF:RCoF, plasma vWF:RCoF/vWF:Ag ratio, plasma
vWF:CBA/vWF:Ag ratio, MDA-AA, platelet vWF:Ag
and vWF:CBA (data not shown) between ET and RT
patients and normal subjects. The multimeric distribu-
tion of platelet vWF was normal in all investigated
cases, either with or without treatment with ASA (data
not shown).
Effect of treatment with ASA
Treatment with ASA resulted in a significant inhibition
of MDA-AA generation, consistent with an effective
inhibition of platelet cyclo-oxygenase activity by ASA
(data not shown). In both patient groups and controls,
Ivy BT was significantly prolonged by ASA (Fig. 1).
However, the BT prolongation was significantly more
in ET patients (DBT 213B132 s) as compared with
both RT patients (DBT 51B63 s, p~0.001) and normal
subjects (DBT 69B55 s, p~0.01). In contrast, there
were no significant differences between normal sub-
jects, RT patients and ET patients in effects of ASA on
either plasma or platelet vWF. In addition, in each pa-
tient or control group, no significant correlations were
observed between changes in plasma or platelet vWF
(or DASA) on one hand and Ivy BT (or DBT) on the
other hand, indicating that it is rather unlikely that
treatment with ASA had caused changes in plasma or
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Table 1 The effect of aspirin (ASA) in Ivy bleeding time, platelet
count, and von Willebrand factor-related parameters in plasma in
normal individuals, patients with reactive thrombocytosis, and
those with essential thrombocythemia. Data are expressed as
mean (SD) (IvyBT Ivy bleeding time, vWF:Ag von Willebrand
factor antigen, vWF:RCoF ristocetin cofactor activity, vWF:CBA
collagen binding activity)
Normal individuals
(np10)
Reactive thrombocytosis
(np10)
Essential thrombocythemia
(np10)
ASAP ASAc ASAP ASAc ASAP ASAc
Ivy BT
(s)
149(60) 218(72)** 177(73) 228(75)* 178(62) 391(167)***
Platelets
(!109/l)
237(36) 250(40) 800(198) 729(264) 689(243) 794(223)
plasma vWF:Ag
(units/ml)
1.36(0.44) 1.38(0.58) 2.57(1.24) 2.31(1.15) 1.52(0.81) 1.23(0.52)
plasma vWF:RCoF
(units/ml)
0.98(0.30) 1.15(0.43) 1.48(1.10) 1.48(0.95) 1.15(0.46) 1.06(0.49)
plasma vWF:CBA
(units/ml)
1.31(0.42) 1.42(0.71) 2.47(1.19) 2.00(1.06) 1.19(1.11) 0.77(0.50)
vWF:RCoF/vWF:Ag
ratio in plasma
0.74(0.16) 0.87(0.25) 0.54(0.24) 0.60(0.13) 0.89(0.47) 0.88(0.38)
vWF:CBA/vWF:Ag
ratio in plasma
0.97(0.17) 1.01(0.14) 0.96(0.34) 0.83(0.20) 0.74(0.37) 0.62(0.28)
Plasma large vWF
multimers (%)
23.1(2.5) 22.0(4.3) 16.4(6.3) 17.5(3.7) 16.6(3.4) 14.2(5.9)
Fig. 1 Ivy BT in 10 patients with essential thrombocythemia
(ET), 10 patients with reactive thrombocytosis (RT) and 10 nor-
mal subjects (N), before (ASA–) and after treatment (ASAc)
with 500 mg ASA for 7 days
Fig. 2 BT in relation to vWF:CBA/vWF:Ag ratios after adminis-
tration of 500 mg ASA for 7 days to 10 normal individuals (open
squares), 10 RT patients (open triangles) and 10 ET patients. Five
ET patients had a normal BT prolongation (open circles) whereas
an excessive BT prolongation (closed circles) was noted in 5 ET
patients. Broken vertical line denotes the upper limit ( p mean
c 2 SD) of normal BT prolongation after 500 mg ASA. Horizon-
tal line indicates the lower limit for vWF:CBA/vWF:Ag ratios of
normal individuals receiving ASA
platelet vWF resulting in an excessive BT prolongation.
However, as shown in Fig. 2, treatment with ASA un-
masked a subgroup of five ET patients who had an ex-
cessive BT prolongation after ASA (524B109 s) in
comparison to ET patients who had a normal prolonga-
tion of BT after ASA (258B82 s, p~0.001), RT pa-
tients (228B5 s, p~0.001) and normal individuals
(218B2 s, p~0.001). All ET patients who showed an
excessive ASA-induced BT prolongation had signifi-
cantly decreased plasma vWF:CBA/vWF:Ag ratios
(n p 5; 0.42B0.07), as compared with the ratios of ET
patients with a normal ASA-induced BT prolongation
(n p 5; 0.83B0.24, p~0.001), RT patients (n p 10;
0.83B0.20, p~0.001) and normal subjects (n p 10;
1.01B0.14, p~0.001). In addition, the five ET patients
with an excessive ASA-induced BT prolongation also
had significantly decreased percentages of large vWF
multimers in plasma (10.9B5.7%) in comparison to ET
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Table 2 Comparison of he-
mostatic parameters between
ET patients with a normal
prolongation (BT normal) and
excessive prolongation (BT
excessive) of the bleeding
time after treatment with as-
pirin. Data are expressed as
mean (SD)
BT normal
(np5)
BT excessive
(np5)
p-value
(t-test)
Ivy BT
(s)
258(82) 524(109) pp0.0024*
Platelets
(!109/l)
722(223) 866(223) pp0.34
MDA-AA
(nmol/109 plts)
0.11(0.17) 0.12(0.19) pp0.93
plasma vWF:Ag
(units/ml)
1.07(0.36) 1.38(0.65) pp0.39
plasma vWF:RCoF
(units/ml)
1.09(0.57) 1.03(0.46) pp0.86
plasma vWF:CBA
(units/ml)
0.95(0.61) 0.59(0.33) pp0.27
vWF:RCoF/vWF:Ag
ratio in plasma
1.00(0.49) 0.75(0.18) pp0.32
vWF:CBA/vWF:Ag
ratio in plasma
0.83(0.24) 0.42(0.07) pp0.0061*
Plasma large vWF
multimers (%)
17.4(4.3) 10.9(5.7) pp0.08*
Platelet vWF:Ag
(U/1011 plts)
16.1(3.7) 15.9(7.9) pp0.96
Platelet vWF:CBA
(U/1011 plts)
14.3(5.0) 12.2(10.1) pp0.69
vWF:CBA/vWF:Ag
ratio in platelets
0.88(0.14) 0.70(0.19) pp0.13
* Also (highly) significant in 4-group analysis N vs RT vs ET BT normal vs ET BT excessive
patients with a normal BT prolongation (17.4B4.3%,
p~0.05), RT patients (17.5B3.7%, p~0.05) and nor-
mal individuals (22.0B4.3%, p~0.001). These data
suggest that inhibition of platelet function by ASA in
the presence of decreased levels of large vWF multim-
ers in plasma may have provoked the excessive BT pro-
longation. Details of the hemostatic parameters of ET
patients with and without an excessive ASA-induced
BT prolongation are shown in Table 2.
Effect of DDAVP on ASA-induced prolongation of
the bleeding time
In a second study, the reduction in large vWF multim-
ers in plasma of ET patients observed in the first study
was corrected in vivo by DDAVP infusion, in parallel
with BT measurements. Consistent with the findings of
the first study, before DDAVP infusion ET patients
had significantly lower plasma vWF:CBA/vWF:Ag ra-
tios and significantly longer ASA-induced BT prolon-
gation; four of ten ET patients even fulfilled the criteria
for excessive BT prolongation (Fig. 3). After DDAVP
infusion vWF:Ag rose from 1.14B0.31 to 3.42B0.82
units/ml (p~0.0001) in normal individuals, and from
1.32B0.59 to 2.79B0.59 units/ml (p~0.0001) in ET pa-
tients. In normal individuals, VWF:CBA rose from
1.31B0.46 to 5.52B2.40 units/ml (p p 0.0002) after
DDAVP, whereas in ET patients vWF:CBA rose from
Fig. 3 The effect of DDAVP-induced changes in large vWF mul-
timers in plasma, given as vWF:CBA/vWF:Ag ratio, on ASA-
induced prolonged BT in 10 patients with ET. Four of them had
an excessive BT prolongation after treatment with 100 mg ASA
for 3 days. Open symbols indicate values before administration of
DDAVP; closed symbols values 1 hour after administration of
DDAVP. Broken vertical line denotes the upper limit of a normal
BT prolongation after 100 mg ASA
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Table 3 Effect of DDAVP on ASA-induced prolongation of bleeding time and plasma vWF:CBA/vWF:Ag ratio in ET patients (ET)
and control subjects (N). Data are given as mean (SD)
Ivy bleeding time (s) vWF:CBA/vWF:Ag ratio
Before After 1 h p-value* Before After 1 h p-value
N
(np10)
292(85) 223(67) pp0.007 1.12(0.15) 1.57(0.41) pp0.004
ET
(np10)
470(179) 289(103) pp0.004 0.85(0.23) 1.24(0.24) pp0.0002
p-value** pp0.011 pp0.11 pp0.006 pp0.04
* Paired t-test (before vs 1 h after DDAVP).
** Student’s t-test (N vs ET).
1.15B0.61 to 3.40B0.72 units/ml (p~0.0001). As
shown in Table 3, both ET patients and control subjects
showed significant increases of vWF:CBA/vWF:Ag ra-
tios after DDAVP. In parallel with a rise of the plasma
vWF:CBA/vWF:Ag ratio, a normalization of BT was
observed in all ET patients (Fig. 3), comparable to BT
of normal individuals before DDAVP infusion. Six
hours after DDAVP infusion a prolongation of BT in
ET patients was observed, which again was associated
with reduced plasma vWF:CBA/vWF:Ag ratios (data
not shown).
Discussion
The BT is frequently used as the method to evaluate
the hemostatic effectiveness of platelets (i.e., primary
hemostasis). Multiple mechanisms of platelet activation
normally assure the efficiency of primary hemostasis.
As a consequence, blockade of one of these pathways,
for instance by ASA, results in only a slight disturbance
of primary hemostasis, as is evidenced by a slight BT
prolongation in normal individuals after ASA. If, how-
ever, potential compensatory pathways of primary he-
mostasis are also affected, for instance by a reduction
of large vWF multimers in plasma, excessive BT pro-
longation and even bleeding may ensue after ingestion
of ASA.
Although the population size of ET patients was
limited, the present study showed that those patients
who had an excessive BT prolongation after ingestion
of ASA had a concurrent decrease of large vWF mul-
timers in plasma. The decrease of large vWF multimers
in plasma was not attributable to treatment with ASA,
since treatment with ASA had no effect on either plas-
ma or platelet vWF. These presented data, however,
suggest that the inhibition of platelet function by ASA
in the presence of concurrently decreased levels of
large vWF multimers in plasma may have provoked the
excessive BT prolongation.
The decrease in large vWF multimers in plasma was
demonstrated by two independent assays, i.e., direct
quantification of large vWF multimers in plasma after
SDS gel electrophoresis of vWF and by ELISA-based
measurements of the plasma vWF:CBA/vWF:Ag ratio.
In a previous study we showed that plasma vWF:CBA/
vWF:Ag ratios are tightly correlated to the percentage
of plasma large vWF multimers [16]. The ristocetin co-
factor activity, which is usually used to test vWF func-
tion in vitro, appeared to be a less sensitive parameter
for detecting modest reductions of large vWF multim-
ers in plasma, consistent with previous observations [7,
14, 16].
The influence of a decreased level of large vWF mul-
timers in plasma on the excessive ASA-induced BT
prolongation was stressed by manipulating the plasma
levels of large vWF multimers by the infusion of
DDAVP. DDAVP releases vWF, including large vWF
multimers, from endothelial storage sites into the circu-
lation [9]. We administered DDAVP to ET patients
with an ASA-induced (excessive) BT prolongation;
plasma vWF:CBA/vWF:Ag ratios rose significantly 1 h
after DDAVP infusion, indicating a rise of plasma lev-
els of large vWF multimers, in parallel with a significant
shortening of the BT, and vice versa 6 h after DDAVP.
These data suggest that an excessive BT prolongation
by ASA in ET may be corrected by normalization of
plasma levels of large vWF multimers.
In previous studies we found that the reduction of
large vWF multimers in plasma in ET is directly related
to the number of circulating platelets [4, 14, 17]. The
reduction of large vWF multimers in plasma becomes
particularly apparent at platelet counts exceeding
1000! 109/l, which even may result in a spontaneous
bleeding tendency due to an acquired von Willebrand
factor deficiency in plasma at higher platelet counts [3,
14]. In accordance with this concept, several epidemio-
logical studies in ET have actually shown an increased
incidence of (mucocutaneous) bleeding when the plate-
let count exceeds the level of 1000! 109/l [2, 8, 17].
However, as is apparent from the present study, the
reduction of large vWF multimers in plasma is also de-
monstrable, albeit modest, at lower platelet counts, i.e.,
below 1000! 109/l. These patients generally do not suf-
fer from overt bleeding but they may have a latent
bleeding tendency. An excessive BT prolongation after
treatment with ASA may identify patients at risk for
bleeding. Although these data require confirmation in
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appropriate clinical trials, they suggest that the reduc-
tion of large vWF multimers in ET may be an impor-
tant determinant factor for bleeding, in particular when
treatment with platelet antiaggregants is considered at
increased platelet counts.
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